Questions about KNR for the current shareholdersI first looked into KNR when it broke out ($3 shares), but back then the market cap was inflated when compared with sales and production capacity.
Now that the shares have gone back down to earth, I'm taking another look.
I do have a few questions about KNR:
Is Biocloud their only horse? Let's say that Biocloud is a failure (either as a tech, as a product or they can't ramp up sales), is the company worthless or do they have other technology and products that hold value?
In the case of Biocloud... From what I've seen, it looks like a stationnary product that gathers "real-time" information about air quality and that can detect covid. In the event that covid is "controlled", what's the incentive to buy the product, and would the product require a significant discount on its current price? What's the detection range (200 sq feet? 2000 sq feet?) per machine, does it need particular placement based on airflow/distance from a window where UV could kill off the virus in the air (and thus some kind of engineering process) in a building? Is there a minimal viral charge required for covid detection? When it detects covid, can it provide an assessment on the contamination level (one individual vs multiple individuals?) Has there been a study on the value provided with investing in on-site detection devices vs investing in other prevention measures (ie: personal protection equipment)? Concerning potential future airborne viruses, is there any guarantee that machines bought now will be able to effectively detect them?
Thank you for your answers, it will help me determine whether the investment risk into KNR is worth it.